Products
Online Inquiry
GSK1059615
Cat. No.:
0225LY-0617
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
GSK1059615 has been included in clinical studies evaluating treatments for lymphoma, endometrial cancer, and various metastatic or solid tumors.
Synonym:
GSK-1059615; 958852-01-2; (Z)-5-((4-(pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione; (5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione; 5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidenedione; 5-{[4-(pyridin-4-yl)quinolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione; 5-((4-(pyridin-4-yl)quinolin-6-yl)methylene)-1,3-thiazolidine-2,4-dione; (5Z)-5-{[4-(pyridin-4-yl)quinolin-6-yl]methylidene}-1,3-thiazolidine-2,4-dione; (5Z)-5-{[4-(4-pyridinyl)-6-quinolinyl]methylidene}-1,3-thiazolidine-2,4-dione
CAS No.:
958852-01-2
Compound CID:
23582824
Formula:
C18H11N3O2S
Formula Weight:
333.36
Specification
Targets&IC50:
PI3Kα: 0.4 nM; PI3Kβ: 0.6 nM; PI3Kδ: 2 nM; mTOR: 12 nM; PI3Kγ: 5 nM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GSK1059615 can be used in signaling research to explore the inhibition of PI3K alpha and its impact on tumor angiogenesis.
Library Information
Target:
mTOR; PI3K
Receptor:
mTOR; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Pathways:
PI3K/Akt/mTOR signaling; Apoptosis
Plate Number:
AOCL-9
Plate Location:
a2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
5 mg/mL; 15 mM
ALogP:
2.496
HBA_Count:
4
HBD_Count:
1
Rotatable Bond:
2
